Trial of JYB1904 in Chronic Spontaneous Urticaria.

Inclusion Criteria:

• Male or female adult subjects (≥18 years of age).

• Diagnosis of Chronic Spontaneous Urticaria(CSU) ≥ 3 months prior to Screening Visit 1 and previously inadequately controlled with a second-generation H1 antihistamine.

• Itching and hives lasting ≥ 6 weeks prior to Screening Visit 1.

• Have a UAS7 (range 0 - 42) ≥ 16, an ISS7 (range 0 - 21) ≥ 6, and an HSS7 (range 0 -

21. ≥ 6 within 7 days prior to randomization.

Exclusion Criteria:

• Induced urticaria with a defined trigger, including artificial urticaria (cutaneousscratches), cold-contact, heat-contact, solar, pressure, delayed-pressure,water-source, cholinergic, or contact urticaria

• Any other dermatological condition with chronic itching, such as atopic dermatitis,herpetic pemphigoid, herpetic dermatitis, senile itching, or psoriasis, which in theopinion of the investigator may affect the study assessment and study results

• Other conditions with symptoms of urticaria or angioedema, including but not limitedto urticarial vasculitis, pigmented urticaria, erythema multiforme, mastocytosis,hereditary urticaria, or acquired/drug-induced urticaria.

• Previous allergic reaction or poor efficacy with omalizumab.

• Contraindication or hypersensitivity to antihistamines (e.g., fexofenadine,loratadine, desloratadine, cetirizine, levocetirizine, rupatadine, bilastine) or anyof the ingredients.